European Radiology

, Volume 27, Issue 5, pp 1795–1803 | Cite as

Expanded polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunts in cirrhotic patients: Long-term patency and clinical outcome results

  • Barbara Geeroms
  • Wim Laleman
  • Annouschka Laenen
  • Sam Heye
  • Chris Verslype
  • Schalk van der Merwe
  • Frederik Nevens
  • Geert Maleux



To retrospectively analyse long-term patency and overall survival of cirrhotic patients treated with TIPSS using e-PTFE-covered stents. Additionally, prognostic factors for better patency and survival were analysed.

Materials and methods

Two hundred and eighty-five consecutive cirrhotic patients with severe portal hypertension-related symptoms were included. Follow-up, including clinical assessment and duplex ultrasound, was analysed up to end of study, patient’s death, liver transplantation or TIPSS-reduction. Patency rates and overall survival were estimated by the Kaplan-Meier method; potential differences in outcome between subgroups were calculated using the Pepe and Mori test.


The 1-, 2- and 5-year primary patencies were 91.5 %, 89.2 % and 86.2 %, respectively, with no new shunt dysfunctions after 5 years’ follow-up. TIPSS revision was performed more often in ascites patients (P = 0.02). The 1-, 4- and 10-year survival rates were 69.2 %, 52.1 % and 30.7 %, respectively. Survival was higher in Child-Pugh class A-B (P = 0.04), in the recurrent bleeding group (P = 0.008) and in patients with underlying alcoholic cirrhosis (P = 0.01).


Long term, primary patency of e-PTFE-covered TIPSS stents remains very high (>80 %); shunt revision was required more frequently in ascites patients. Overall survival was better in Child-Pugh A-B patients with recurrent variceal bleeding and alcoholic liver cirrhosis.


Long-term primary patency rate of e-PTFE-covered TIPSS stents remains very high.

No new shunt dysfunction was found after 5 years of follow-up.

Shunt revision was required more frequently in ascites patients.

Four and 10 years’ overall survival was 50 and 30 %, respectively.


Transjugular intrahepatic portosystemic shunt Portal hypertension Cirrhosis Covered stent Long-term outcome 



The scientific guarantor of this publication is Geert Maleux. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. The Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven and University of Hasselt, Belgium kindly provided statistical advice for this manuscript. Institutional Review Board approval was obtained.

Written informed consent was not required for this study because it was a retrospective, observational study. Methodology: retrospective, observational, performed at one institution.


  1. 1.
    Tripathy D, Helmy A, Macbeth K et al (2004) Ten years’ follow-up of 472 patients following transjugular intrahepatic portosystemic stent-shunt insertion at a single centre. Eur J Gastroenterol Hepatol 16:9–18CrossRefGoogle Scholar
  2. 2.
    Ter Borg P, Hollemans M, Van Buuren H et al (2004) Transjugular intrahepatic portosystemic shunts: long-term patency and clinical results in a patient cohort observed for 3–9 years. Radiology 231:537–545CrossRefPubMedGoogle Scholar
  3. 3.
    Riggio O, Ridola L, Angeloni S et al (2010) Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol 53:267–272CrossRefPubMedGoogle Scholar
  4. 4.
    Bureau C, Pagan J, Layrargues G et al (2007) Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicenter study. Liver Int 27:742–747CrossRefPubMedGoogle Scholar
  5. 5.
    Rössle M, Siegerstetter V, Euringer W et al (2006) The use of polytetrafluoroethylene-covered stent graft for transjugular intrahepatic portosystemic shunt (TIPS): Long-term follow-up of 100 patients. Acta Radiol 47:660–666CrossRefPubMedGoogle Scholar
  6. 6.
    Vignali C, Bargellini I, Grosso M et al (2005) TIPS with expanded polytetrafluoroethylene-covered stent: results of an Italian multicenter study. Am J Roentgenol 185:472–480CrossRefGoogle Scholar
  7. 7.
    Charon J, Alaeddin F, Pimpalwar S et al (2004) Results of a retrospective multicenter trial of the Viatorr expanded polytetraethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 15:1219–1230CrossRefPubMedGoogle Scholar
  8. 8.
    Maleux G, Nevens F, Wilmer A et al (2004) Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosytemic shunt procedures. Eur Radiol 14:1842–1850CrossRefPubMedGoogle Scholar
  9. 9.
    Angeloni S, Merli M, Salvatori F et al (2004) Polytetrafluoroethylene-covered stent grafts for TIPS procedure: 1-year patency and clinical results. Am J Gastroenterol 99:280–285CrossRefPubMedGoogle Scholar
  10. 10.
    Bureau C, Garcia-Pagan J, Otal P et al (2004) Improved clinical outome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 126:469–475CrossRefPubMedGoogle Scholar
  11. 11.
    Angermayr B, Cejna M, Koenig F et al (2003) Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 38:1043–1050CrossRefPubMedGoogle Scholar
  12. 12.
    Maleux G, Perez-Gutierrez N, Evrard S et al (2010) Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study. Acta Gastroenterol Belg 73:336–341PubMedGoogle Scholar
  13. 13.
    Rossi P, Salvatori F, Fanelli F et al (2004) Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology 231:820–830CrossRefPubMedGoogle Scholar
  14. 14.
    Hausegger K, Karnel F, Georgieva B et al (2004) Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol 15:239–248CrossRefPubMedGoogle Scholar
  15. 15.
    Cejna M, Peck-Radosavljevic M, Thurnher S, Hittmair K, Schoder M, Lammer J (2001) Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with polytetrafluoroethylene-covered nitinol endoprosthesis. Radiology 221:437–446CrossRefPubMedGoogle Scholar
  16. 16.
    Weber C, Nadolski G, White S et al (2015) Long-term patency and clinical analysis of expanded polytetrafluoroethylene-covered transjugular intrahepatic portosystemic shunt stent grafts. J Vasc Interv Radiol 26:1257–1265, Quiz 1265CrossRefPubMedGoogle Scholar
  17. 17.
    Zhuang Z, Teng G, Jeffery R, Gemery J, Janne d’Othee B, Bettmann M (2002) Long-term results and quality of life in patients treated with transjugular intrahepatic shunts. Am J Roentgenol 179:1597–1603CrossRefGoogle Scholar
  18. 18.
    Bercu Z, Fischman A, Kim E et al (2015) TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. Am J Roentgenol 204:654–661CrossRefGoogle Scholar
  19. 19.
    Montgomery A, Ferral H, Vasan R, Postoak D (2005) MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol 28:307–312CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2016

Authors and Affiliations

  • Barbara Geeroms
    • 1
    • 2
  • Wim Laleman
    • 3
  • Annouschka Laenen
    • 4
    • 5
  • Sam Heye
    • 1
    • 2
  • Chris Verslype
    • 3
  • Schalk van der Merwe
    • 3
  • Frederik Nevens
    • 3
  • Geert Maleux
    • 1
    • 2
  1. 1.Department of RadiologyUniversity Hospitals LeuvenLeuvenBelgium
  2. 2.Department of Imaging and PathologyKU LeuvenLeuvenBelgium
  3. 3.Department of HepatologyUniversity Hospitals LeuvenLeuvenBelgium
  4. 4.Interuniversity Institute for Biostatistics and Statistical BioinformaticsKU LeuvenLeuvenBelgium
  5. 5.University of HasseltHasseltBelgium

Personalised recommendations